The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (HO151DLBCL)
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
A PHASE2 clinical study on DLBCL and NHL, this trial is ongoing. The trial is conducted by Stichting Hemato-Oncologie voor Volwassenen Nederland and has accumulated 16 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Oct 2018 — Mar 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stichting Hemato-Oncologie voor Volwassenen Nederland
For direct contact, visit the study record on ClinicalTrials.gov .